FDA 483 - Adam M. Sun, M.D - February 25, 2022

Adam M. Sun, M.D. in Rosemead, CA, was cited for significant deficiencies in clinical trial conduct during an FDA inspection. Observations included failures to conduct investigations according to protocol, delayed reporting of adverse events to the sponsor, inadequate investigational drug disposition records, and inaccurate case histories. These issues indicate a lack of adherence to regulatory requirements for clinical investigations.